Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis - Trial SLCTR_2018_025
Access comprehensive clinical trial information for SLCTR_2018_025 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Gilead Sciences, Inc and is currently Terminated. The study focuses on Ulcerative Colitis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2018_025
Phase 2/3
Terminated
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2018_025
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis
Study Focus
Interventional
Sponsor & Location
Gilead Sciences, Inc
Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Singapore, Sl
Timeline & Enrollment
Phase 2/3
N/A
N/A
ICD-10 Classifications
Ulcerative colitis
Other ulcerative colitis
Ulcerative colitis, unspecified
Arthropathy in ulcerative colitis
Juvenile arthritis in ulcerative colitis
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2018_025
Non-Device Trial